The growing galectin network in colon cancer and clinical relevance of cytoplasmic galectin-3 reactivity
2013; International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts; Volume: 33; Issue: 8 Linguagem: Inglês
ISSN
1791-7530
AutoresHeather Anne Elizabeth Dawson, Sabine André, Eva Karamitopoulou, Inti Zlobec, Hans‐Joachim Gabius,
Tópico(s)Toxin Mechanisms and Immunotoxins
ResumoBACKGROUND/AIM Human lectins translate sugar-encoded signals of cell surface glycoconjugates into biological effects, and this is what is known for the adhesion/growth-regulatory galectins. In addition, the multifunctional members of this group can be intracellular, binding to distinct proteins. The presence of galectins and galectin reactivity were exemplarily studied in the present article. MATERIALS AND METHODS We combined immuno- and lectin histochemical monitoring in colon cancer on tissue arrays. RESULTS Intracellular presence of galectins-7 and -9 in colon cancer is detected, extending the previously known set of five expressed lectins this tumor type. The assumed significance of intracellular galectin presence, e.g. for an interplay with BCL2, β-catenin, oncogenic KRAS or synexin, is underscored by respective staining with labeled galectin-3. Statistical significance was obtained for galectin-3 staining with respect to tumor differentiation (p=0.0376), lymph node metastasis (p=0.0069) and lymphatic invasion (p=0.0156). Survival was correlated to staining, galectin-3 reactivity indicating a favorable prognosis (p=0.0183), albeit not as an independent marker. No correlation to KRAS/BRAF status was detected. CONCLUSION These results encourage further testing of labeled human galectins as probes and immunohistochemical fingerprinting instead of measuring single or few activities, in colon cancer and other tumor types.
Referência(s)